Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Doravirine (Pifeltro®) is recommended as an option for use within NHS Wales, in combination with other antiretroviral products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | doravirine (Pifeltro®) | ||
| Formulation | 100 mg film-coated tablet | ||
| Reference number | 3109 | ||
| Indication | In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class |
||
| Company | Merck Sharp & Dohme Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0920 | ||
| NMG meeting date | 22/07/2020 | ||
| AWMSG meeting date | 15/09/2020 | ||
| Date of issue | 24/09/2020 | ||
| Commercial arrangement | WPAS | ||